Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
Ana Cristina de Medeiros Ribeiro, Nádia Emi Aikawa, Carla Gonçalves Schahin Saad, et al.
Nature Medicine (2021) Vol. 27, Iss. 10, pp. 1744-1751
Open Access | Times Cited: 175

Showing 1-25 of 175 citing articles:

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
Myron J. Levin, Andrew Ustianowski, Stéphane De Wit, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 23, pp. 2188-2200
Open Access | Times Cited: 614
Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis
Ainsley Ryan Yan Bin Lee, Shi Yin Wong, Louis Yi Ann Chai, et al.
BMJ (2022), pp. e068632-e068632
Open Access | Times Cited: 390
COVID-19 vaccine development: milestones, lessons and prospects
Maochen Li, Han Wang, Lili Tian, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 331
Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review
Simon Galmiche, Liêm Binh Luong Nguyen, Éric Tartour, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 163-177
Open Access | Times Cited: 175
Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry
Pedro Machado, Saskia Lawson‐Tovey, Anja Strangfeld, et al.
Annals of the Rheumatic Diseases (2021) Vol. 81, Iss. 5, pp. 695-709
Open Access | Times Cited: 167
Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong
Xue Li, Xinning Tong, Winnie Wan Yin Yeung, et al.
Annals of the Rheumatic Diseases (2021) Vol. 81, Iss. 4, pp. 564-568
Open Access | Times Cited: 108
Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study
Jing Lian Suah, Masliyana Husin, Peter Seah Keng Tok, et al.
International Journal of Infectious Diseases (2022) Vol. 119, pp. 69-76
Open Access | Times Cited: 67
Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations
Féline P B Kroon, Aurélie Najm, Alessia Alunno, et al.
Annals of the Rheumatic Diseases (2021) Vol. 81, Iss. 3, pp. 422-432
Open Access | Times Cited: 92
Efficacy of COVID-19 vaccines in immunocompromised patients: A systematic review and meta-analysis
Ainsley Ryan Yan Bin Lee, Shi Yin Wong, Louis Yi Ann Chai, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 83
A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues
Shahad Saif Khandker, Brian Godman, Md. Irfan Jawad, et al.
Vaccines (2021) Vol. 9, Iss. 12, pp. 1387-1387
Open Access | Times Cited: 72
Safety and disease flare of autoimmune inflammatory rheumatic diseases: a large real-world survey on inactivated COVID-19 vaccines
Yong Fan, Yan Geng, Yu Wang, et al.
Annals of the Rheumatic Diseases (2021) Vol. 81, Iss. 3, pp. 443-445
Open Access | Times Cited: 55
CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2
Lairun Jin, Zhuopei Li, Xiaoyin Zhang, et al.
Human Vaccines & Immunotherapeutics (2022) Vol. 18, Iss. 6
Open Access | Times Cited: 55
Dynamics of antibody response to CoronaVac vaccine
Marcela Helena Gambim Fonseca, Tamiris de Fátima Goebel de Souza, Fernanda Montenegro de Carvalho Araújo, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 5, pp. 2139-2148
Open Access | Times Cited: 54
ANCA-associated vasculitis following ChAdOx1 nCoV19 vaccination: case-based review
Arun Prabhahar, Shankar Naidu, Prabhat Chauhan, et al.
Rheumatology International (2022) Vol. 42, Iss. 4, pp. 749-758
Open Access | Times Cited: 53
Early experience of COVID‐19 vaccine‐related adverse events among adolescents and young adults with rheumatic diseases: A single‐center study
Fatih Haşlak, Aybüke Günalp, Memnune Nur Çebi, et al.
International Journal of Rheumatic Diseases (2022) Vol. 25, Iss. 3, pp. 353-363
Closed Access | Times Cited: 49
Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study
Lucas Chaves Netto, Karim Yaqub Ibrahim, Camila de Melo Picone, et al.
The Lancet HIV (2022) Vol. 9, Iss. 5, pp. e323-e331
Open Access | Times Cited: 48
An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey
Derya Çağlayan, Ahmet Furkan SÜNER, Neslişah Şiyve, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 5, pp. 2212-2221
Open Access | Times Cited: 44
Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases
Nádia Emi Aikawa, Léonard de Vinci Kanda Kupa, Ana Cristina de Medeiros Ribeiro, et al.
Annals of the Rheumatic Diseases (2022) Vol. 81, Iss. 7, pp. 1036-1043
Open Access | Times Cited: 39
COVID‐19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathies
Albert Gil‐Vila, R Naveen, Albert Selva-O’Callaghan, et al.
Muscle & Nerve (2022) Vol. 66, Iss. 4, pp. 426-437
Open Access | Times Cited: 38
Serologic Response to Coronavirus Disease 2019 (COVID-19) Vaccination in Patients With Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-analysis
Atsushi Sakuraba, Alexander Luna, Dejan Micić
Gastroenterology (2021) Vol. 162, Iss. 1, pp. 88-108.e9
Open Access | Times Cited: 51
Neutralization of SARS-CoV-2 Variants in Transplant Recipients After Two and Three Doses of mRNA-1273 Vaccine
Deepali Kumar, Victor H. Ferreira, Victoria Hall, et al.
Annals of Internal Medicine (2021) Vol. 175, Iss. 2, pp. 226-233
Open Access | Times Cited: 48
BNT162b2 mRNA COVID-19 vaccine and booster in patients with autoimmune rheumatic diseases: a national cohort study
Amir Bieber, Iftach Sagy, Lena Novack, et al.
Annals of the Rheumatic Diseases (2022) Vol. 81, Iss. 7, pp. 1028-1035
Open Access | Times Cited: 34
Reduced Immune Response to Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Cohort of Immunocompromised Patients in Chile
María Elvira Balcells, Nicole Le Corre, Josefina Durán, et al.
Clinical Infectious Diseases (2022) Vol. 75, Iss. 1, pp. e594-e602
Open Access | Times Cited: 33
Safety of an inactivated, whole-virion COVID-19 vaccine (CoronaVac) in people aged 60 years or older in Hong Kong: a modified self-controlled case series
Eric Yuk Fai Wan, Yuan Wang, Celine Sze Ling Chui, et al.
The Lancet Healthy Longevity (2022) Vol. 3, Iss. 7, pp. e491-e500
Open Access | Times Cited: 31
Immunogenicity and safety of inactivated and mRNA COVID-19 vaccines in patients with systemic lupus erythematosus
Ho So, Tena Li, Vivien Kin Yi Chan, et al.
Therapeutic Advances in Musculoskeletal Disease (2022) Vol. 14
Open Access | Times Cited: 28
Page 1 - Next Page

Scroll to top